Cash, cash equivalents and marketable securities totaled $168.0 million as of December 31, 2024. This balance excludes net proceeds from our IPO of $199.6 million after deducting underwriting discounts and commissions and other offering costs. With the net IPO proceeds, Sionna expects its current cash position to fund operations into 2028.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SION:
- Okta upgraded, Quest Diagnostics downgraded: Wall Street’s top analyst calls
- Sionna Therapeutics initiated with a Buy at TD Cowen
- Goldman Sachs starts Sionna Therapeutics with Early-Stage Biotech designation
- Innovative Approach to Cystic Fibrosis Treatment: Sionna Therapeutics’ Pioneering Pipeline Earns Buy Rating
- Sionna Therapeutics initiated with a Buy at Stifel